Targeting cells in motion: Migrating toward improved therapies. Issue 6 (13th May 2013)

• Record Type: Journal Article
• Authors: Griffith, Jason W.; Luster, Andrew D.
• Is Part Of: European journal of immunology. Volume 43:Issue 6(2013:Jun.)
• Page Start: 1430
• Page End: 1435
• Publication Date: 2013-05-13
• Subjects: Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.201243183
• Languages: English
• ISSNs: 0014-2980

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The development of clinical therapeutics that interfere with the migration of leukocytes has revolutionized the treatment of multiple sclerosis and holds great promise for the treatment of a wide range of inflammatory diseases. As the molecules essential for the multi‐step adhesion cascade that mediates cellular migration have been elucidated, the number of potential targets available to modulate leukocyte trafficking has increased exponentially. In this Viewpoint, we briefly review our current understanding of these mole‐cular targets and how these targets vary by tissue and leukocyte subset with emphasis on T cells. We then describe the two currently approved therapeutics that target cell migration, natalizumab and fingolimod, and discuss how an improved understanding of their function could pave the way for the development of safer and more efficacious therapies for inflammatory and autoimmune diseases.</p> </abstract>